newsfilter
← Latest News
GlobeNewswire·

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer's Patients Treated with Anti-Amyloid Therapies BOSTON,